Ok, let's take your point. The current state of
Post# of 148050
The current state of leronlimab in development is, as my Magic 8 Ball tells me this fine Friday morning, "Reply hazy, try again later."
Market conditions? Well, Covid, cancer, NASH, and HIV all suck and need a great drug. Is that leronlimab? We hope so, but we shareholders are currently in the dark as to the most recent development of the product. Again, I point to the SP in terms of value and what a BO offer might actually be, given the norm for multiples of SP as a price.